These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27978521)

  • 1. The Hyperfiltering Kidney in Diabetes.
    Trevisan R; Dodesini AR
    Nephron; 2017; 136(4):277-280. PubMed ID: 27978521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
    Škrtić M; Cherney DZ
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
    Cherney DZ; Perkins BA
    Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
    Toto RD
    Nephron; 2017; 137(1):64-67. PubMed ID: 28743130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
    Rajasekeran H; Cherney DZ; Lovshin JA
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
    Dekkers CCJ; Gansevoort RT; Heerspink HJL
    Curr Diab Rep; 2018 Mar; 18(5):27. PubMed ID: 29589183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate.
    Premaratne E; Macisaac RJ; Tsalamandris C; Panagiotopoulos S; Smith T; Jerums G
    Diabetologia; 2005 Dec; 48(12):2486-93. PubMed ID: 16261309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal hyperfiltration is associated with glucose-dependent changes in fractional excretion of sodium in patients with uncomplicated type 1 diabetes.
    Yang GK; Har RL; Lytvyn Y; Yip P; Cherney DZ
    Diabetes Care; 2014 Oct; 37(10):2774-81. PubMed ID: 25011944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus.
    Har R; Scholey JW; Daneman D; Mahmud FH; Dekker R; Lai V; Elia Y; Fritzler ML; Sochett EB; Reich HN; Cherney DZ
    Diabetologia; 2013 May; 56(5):1166-73. PubMed ID: 23412605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperfiltration and diabetic nephropathy: is it the beginning? Or is it the end?
    Castellino P; Shohat J; DeFronzo RA
    Semin Nephrol; 1990 May; 10(3):228-41. PubMed ID: 2190280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
    Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
    Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
    Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
    Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sweet success? SGLT2 inhibitors and diabetes.
    Layton AT
    Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1034-F1035. PubMed ID: 29357429
    [No Abstract]   [Full Text] [Related]  

  • 17. SGLT-2 inhibition in patients with kidney disease.
    Gilbert RE
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S23-7. PubMed ID: 25554068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative renal pathophysiology relevant to IDDM and NIDDM patients.
    Mogensen CE; Schmitz A; Christensen CK
    Diabetes Metab Rev; 1988 Aug; 4(5):453-83. PubMed ID: 3061756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
    Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes-induced hyperfiltration in adenosine A(1)-receptor deficient mice lacking the tubuloglomerular feedback mechanism.
    Sällström J; Carlsson PO; Fredholm BB; Larsson E; Persson AE; Palm F
    Acta Physiol (Oxf); 2007 Jul; 190(3):253-9. PubMed ID: 17581137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.